rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Beth C. Seidenberg

Director and 10% owner

Company insider

Files Form 4 as: Director and 10% owner, Latigo Biotherapeutics; Director, Sagimet Biosciences; Director and 10% owner, Kyverna Therapeutics; Director, Vera Therapeutics; Director and 10% owner, Acelyrin; Director, Progyny; Director and 10% owner, Atara Biotherapeutics; Director and 10% owner, Epizyme.

Every Form 4 they filed

In numbers

Trades disclosed
317
Buys
26
Sells
8
Bought
$83.7M
Sold
$16.0M
Companies
11
Companies where not an officer
11
First trade
3 May 2006
Last trade
10 Aug 2026
Last filed
10 Aug 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
LTGO Latigo BiotherapeuticsDirector, 10% owner · Biotechnology · last 10 Aug 20260 buys · 0 sells
SGMT Sagimet BiosciencesDirector · Biotechnology · last 12 Jun 20261 buy · 0 sells
KYTX Kyverna TherapeuticsDirector, 10% owner · Biotechnology · last 27 May 20261 buy · 0 sells
VERA Vera TherapeuticsDirector · Biotechnology · last 21 May 202619 buys · 3 sells
AcelyrinDirector, 10% owner · last 21 May 20251 buy · 0 sells
PGNY ProgynyDirector · Providers & Facilities · last 23 May 20241 buy · 4 sells
ATRA Atara BiotherapeuticsDirector, 10% owner · Biotechnology · last 31 May 20230 buys · 0 sells
EpizymeDirector, 10% owner · last 30 Jun 20190 buys · 1 sell
TesaroDirector · last 22 Jan 20192 buys · 0 sells
ARMO BioSciencesDirector, 10% owner · last 22 Jun 20180 buys · 0 sells
BCRX BioCryst PharmaceuticalsDirector · Biotechnology · last 13 May 20101 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
01Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
10 Aug 2026filed 10 Aug 2026LTGO Latigo BiotherapeuticsBiotechnologySEC FORM 4 Code C—938,979filing
10 Aug 2026filed 10 Aug 2026LTGO Latigo Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—1,027,635filing
10 Aug 2026filed 10 Aug 2026LTGO Latigo Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—3,464,072filing
10 Aug 2026filed 10 Aug 2026LTGO Latigo Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—1,484,401filing
10 Aug 2026filed 10 Aug 2026LTGO Latigo Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—2,066,857filing
10 Aug 2026filed 10 Aug 2026LTGO Latigo Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—165,519filing
10 Aug 2026filed 10 Aug 2026LTGO Latigo BiotherapeuticsBiotechnologySEC FORM 4 Code C—3,547,842filing
10 Aug 2026filed 10 Aug 2026LTGO Latigo BiotherapeuticsBiotechnologySEC FORM 4 Code C—1,027,635filing
10 Aug 2026filed 10 Aug 2026LTGO Latigo Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—938,979filing
10 Aug 2026filed 10 Aug 2026LTGO Latigo Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—3,547,842filing
10 Aug 2026filed 10 Aug 2026LTGO Latigo Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—1,027,635filing
10 Aug 2026filed 10 Aug 2026LTGO Latigo Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—3,464,072filing
10 Aug 2026filed 10 Aug 2026LTGO Latigo Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—1,484,401filing
10 Aug 2026filed 10 Aug 2026LTGO Latigo Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—2,066,857filing
10 Aug 2026filed 10 Aug 2026LTGO Latigo Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—165,519filing
10 Aug 2026filed 10 Aug 2026LTGO Latigo BiotherapeuticsBiotechnologySEC FORM 4 Code C—3,464,072filing
10 Aug 2026filed 10 Aug 2026LTGO Latigo BiotherapeuticsBiotechnologySEC FORM 4 Code C—1,484,401filing
10 Aug 2026filed 10 Aug 2026LTGO Latigo BiotherapeuticsBiotechnologySEC FORM 4 Code C—165,519filing
10 Aug 2026filed 10 Aug 2026LTGO Latigo BiotherapeuticsBiotechnologySEC FORM 4 Code C—2,066,857filing
10 Aug 2026filed 10 Aug 2026LTGO Latigo Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—938,979filing

Sectors

Health Care30
Not placed4

Buys in green, sells in red, by the company’s sector.

Related people

Marshall FordycePresident and CEO · President and CEO at Vera Therapeutics, filing Form 4 there in the last year
Joseph R. YoungSVP, Finance, Chief Acct Offcr · SVP, Finance, Chief Acct Offcr at Vera Therapeutics, filing Form 4 there in the last year
George KembleDirector · Director at Sagimet Biosciences, filing Form 4 there in the last year
5AM Ventures VI, L.P.10% owner · 10% owner at Latigo Biotherapeutics, filing Form 4 there in the last year
Sanofi10% owner · 10% owner at Latigo Biotherapeutics, filing Form 4 there in the last year
Melissa B. CummingsChief Operating Officer · Also traded PGNY in the last 90 days
Allison SwartzEVP, Gc · Also traded PGNY in the last 90 days
Kevin K. GordonDirector · Also traded PGNY in the last 90 days